Overview

A Study for Participants With Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2018-09-05
Target enrollment:
Participant gender:
Summary
This study will compare the effects of Enzastaurin plus Sunitinib versus Sunitinib alone in metastatic Renal Cell Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Sunitinib